8-K 1 sava-20200914x8k.htm 8-K

﻿

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 14, 20 20

___________________

Cassava Sciences, Inc.

(Exact name of registrant as specified in its charter)

___________________

Delaware |  | 000-29959 |  | 91-1911336
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification Number)

﻿

7801 N Capital of Texas Highway, Suite 260

Austin, Texas 78731

(Address of principal executive offices, including zip code)

(512) 501-2444

(Registrant’s telephone number, including area code)

﻿

Not Applicable

(Former name or former address, if changed since last report.)

___________________

﻿

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

﻿ |
☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

﻿

﻿

Securities registered pursuant to Section 12(b) of the Act:

﻿

0 |  |  |  |
Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.001 par value |  | SAVA |  | NASDAQ Capital Market

﻿

﻿

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

﻿

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ☐

Item 7.01. Regulation FD Disclosure.

﻿

A copy of the Cassava Sciences, Inc. Final Results of a Phase 2b Study of Sumifilam in Alzheimer’s Disease presentation, dated September 14, 2020, is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

﻿

Item 8.01. Other Events.

﻿

On September 14, 20 20, Cassava Sciences, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

﻿

Item 9.01 Financial Statements and Exhibits.

﻿

﻿ |  |
(d) Exhibit No. Description
﻿ |  |
﻿99.1 |  | Cassava Sciences, Inc. Final Results of a Phase 2b Study of Sumifilam in Alzheimer’s Disease presentation, dated September 14, 2020
﻿99.2 |  | Cassava Sciences, Inc. press release dated September 14, 2020

﻿

SIGNATURE

﻿

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

﻿

﻿ |  |
﻿ | CASSAVA SCIENCES, INC.
﻿ | a Delaware corporation
Date: September 14, 20 20 |  |
| By: | /s/ ERIC J. SCHOEN
|  | Eric J. Schoen
|  | Chief Financial Officer

﻿